#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuropathic arthropathy Pancreatic carcinoma metastatic Non-small cell lung cancer Metastases to peritoneum Ornithine transcarbamoylase deficiency Chronic graft versus host disease in intestine Myeloproliferative neoplasm Chronic myeloid leukaemia (in remission) Chordoma IgA nephropathy Basal cell naevus syndrome Marginal zone lymphoma recurrent Eosinophilic granulomatosis with polyangiitis Mantle cell lymphoma stage IV Cardiac failure acute More trials…

    Learn about Rare Diseases

    Factor VIII deficiency – Life with Disease Glycogen storage disease type I – Treatment Pemphigoid – Trials in Disease Cystic fibrosis lung Angiosarcoma recurrent – Treatment Myelodysplastic syndrome with excess blasts Osteosarcoma – Treatment Retinitis pigmentosa – Trials in Disease Mucopolysaccharidosis III – Life with Disease Paraneoplastic neurological syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Treosulfan Baxdrostat Fexofenadine Sodium Laurilsulfate Sodium Nitrite Narsoplimab Sodium Lactate Solution Azd3427 Valiltramiprosate Selexipag TRV045 Sodium Nitroprusside Dihydrate Aup1602-C Erythromycin Lactobionate GSKVX000000039711 Dexketoprofen Pemetrexed Disodium Danicopan Tovinontrine DISODIUM PHOSPHATE More therapies…

    Learn about Your Condition

    Primary adrenal insufficiency Extraskeletal ossification Chronic disease Chorioretinitis Tendon rupture Alcoholism Transferrin decreased Muscle injury Skin bacterial infection Optic atrophy Adrenocortical carcinoma Glycogen storage disorder Anaemia of pregnancy Colorectal cancer stage IV Immune system disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mijlenmeersstraat 90, Anderlecht, 1070, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Zolbetuximab combined with Paclitaxel and Ramucirumab for patients with previously treated CLDN18.

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Zolbetuximab
    Belgium

  • Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Docetaxel
    Belgium France Germany Ireland Italy The Netherlands +2

  • Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Belgium France Spain

  • Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

    Recruiting

    3 1
    Investigated Drugs:
    • IBUZATRELVIR
    • Remdesivir
    Belgium Denmark France Germany Greece The Netherlands +3

  • Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Docetaxel
    • Infliximab
    Austria Belgium Denmark Finland France Germany +7

  • Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal squamous cell carcinoma
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    • Docetaxel
    • Irinotecan Hydrochloride
    Belgium Denmark France Germany Italy The Netherlands +5

  • Study on RSV Vaccination with Abrysvo and Arexvy for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Allogenic stem cell transplantation
    Investigated Drugs:
    • Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
    Belgium

  • Study Comparing Two Drug Combinations for Blood Cancer Patients: Rabbit Anti-Human Thymocyte Immunoglobulin vs. Anhydrous Cyclophosphamide

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Autologous haematopoietic stem cell transplant
    Investigated Drugs:
    • Rabbit Anti-Human Thymocyte Immunoglobulin
    • Anhydrous Cyclophosphamide
    Belgium

  • Study on the Safety and Effectiveness of Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Hormone Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • Breast cancer female
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capivasertib
    Belgium Germany Portugal

  • Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elranatamab
    • Daratumumab
    • Human Normal Immunoglobulin
    Belgium France
Previous Page
1 2 3 4 5 6 … 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!